Press & Media Coverage
Catch up on our latest press coverage
Imagion Biosystems receives AU$2.5 million in R&D tax incentives
ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
The Market Herald Interview Discussing First-of-its-Kind Magnetic Imaging Technology
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Fear and Greed Podcast Discussing Precise Imaging Solutions to Detect Cancers
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
2022 Switzer Small & Micro Cap Conference Presentation
Imagion Bio CEO, Robert Proulx, presents company information to investors at the 2022 Switzer Small & Micro Cap Conference in September. Video Transcript: Thank you,
Imagion to Present Prostate Cancer Research Data at WMIC 2022
https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
Half-Year Results for the First Half of 2022 and Appendix 4D
Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast
Watch our latest media coverage
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.